Higher oral semaglutide doses have been studied for weight loss in people without diabetes, expanding its potential uses
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease
The people who made it through understood the timeline, prepared for peak side effect weeks, and followed specific protocols
None of the clinical efficacy studies described below was conducted with JANUMET
Indeed, activation of the sympathetic nervous system activates immune cells, which have also been reported to be potentially beneficial to the host 49
Discontinuation rates within the first year are consistently reported between approximately 45 and 75% (Sikirica et al., 2017